Similar articles

• Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.

  Serenelli M, Jackson A, Dewan P, Jhund PS, Petrie MC, Rossignol P, Campo G, Pitt B, Zannad F, Ferreira JP, McMurray JJV. Serenelli M, et al. JACC Heart Fail. 2020 Mar;8(3):188-198. doi: 10.1016/j.jchf.2019.09.011. Epub 2020 Jan 8. JACC Heart Fail. 2020. PMID: 31926854 Free PMC article. Clinical Trial.
• Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction.

  Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Brunner-La Rocca HP, Januzzi JL Jr. Gandhi PU, et al. Am Heart J. 2015 Mar;169(3):404-411.e3. doi: 10.1016/j.ahj.2014.12.012. Epub 2015 Jan 7. Am Heart J. 2015. PMID: 25728731 Clinical Trial.
• Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.

  Jonsson A, Norberg H, Bergdahl E, Lindmark K. Jonsson A, et al. Cardiovasc Ther. 2018 Oct;36(5):e12459. doi: 10.1111/1755-5922.12459. Epub 2018 Aug 14. Cardiovasc Ther. 2018. PMID: 30019390 Free PMC article.
• Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

  Kapelios CJ, Murrow JR, Nührenberg TG, Montoro Lopez MN. Kapelios CJ, et al. Heart Fail Rev. 2019 May;24(3):367-377. doi: 10.1007/s10741-018-9758-0. Heart Fail Rev. 2019. PMID: 30618017 Free PMC article.
• Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease.

  Khan MS, Khan MS, Moustafa A, Anderson AS, Mehta R, Khan SS. Khan MS, et al. Am J Cardiol. 2020 Feb 15;125(4):643-650. doi: 10.1016/j.amjcard.2019.11.014. Epub 2019 Nov 19. Am J Cardiol. 2020. PMID: 31843235 Free PMC article.